MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 1, 2004; DOI: 10.1124/mol.104.002956


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.002956v1
66/4/834    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosemond, E.
Right arrow Articles by Hampson, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosemond, E.
Right arrow Articles by Hampson, D. R.


Received for publication May 19, 2004.
Revised June 30, 2004.
Accepted for publication July 1, 2004.

Molecular Basis for the Differential Agonist Affinities of Group III Metabotropic Glutamate Receptors

Erica Rosemond 1, Minghua Wang 1, Yi Yao 1, Laura Storjohann 2, Thomas Stormann 2, Edwin C. Johnson 3, David Richard Hampson 1*

1 U. of Toronto 2 NPS Pharmaceuticals 3 AstraZeneca

* Address correspondence to: E-mail: d.hampson{at}utoronto.ca

Abstract

Agonist stimulation of Group III metabotropic glutamate receptors (mGluRs) induces an inhibition of neurotransmitter release from neurons. The Group III mGluRs are pharmacologically defined by activation with the glutamate analog L-amino-4-phosphonobutyric acid (L-AP4). The affinities of these receptors for L-AP4 and glutamate vary over approximately a 1500-fold concentration range. The goal of this study was to elucidate the molecular basis for this dispersion of agonist affinities for the Group III receptors mGluR4, mGluR6, and mGluR7. [3H]L-AP4 binding was present in human embryonic kidney cells transfected with the high affinity mGluR4 receptor but not in cells transfected with mGluR6 or the low affinity mGluR7 receptor. Analysis of mGluR4/mGluR6 receptor chimeras revealed that replacement of the first 35 amino acids of mGluR6 with the first 50 amino acids of mGluR4 was sufficient to impart [3H]L-AP4 binding to mGluR6. Homology models of mGluR4 and mGluR7 were employed to predict amino acids that may affect ligand affinity. Mutations were made in mGluR7 to convert selected residues into the equivalent amino acids present in the high affinity mGluR4 receptor. The mGluR7 N74K mutation caused a 12-fold increase in affinity in a functional assay, while the N74K mutation in combination with mutations in residues 258 - 262, which lie outside the binding pocket, caused a 112-fold increase in affinity compared to unmutated mGluR7. Our results demonstrate that the binding site residues at position lysine 74 in mGluR4, glutamine 58 in mGluR6, and asparagine 74 in mGluR7 are key determinants of agonist affinity and that additional residues situated outside of the binding pocket, including those present in the extreme amino terminus, also contribute to agonist affinity and the pharmacological profiles of the Group III mGluRs.


Key words: Metabotropic glutamate, Structure-activity relationships and modeling, Func. analysis receptor/ion channel mutants, Fluorescence techniques, Mutagenesis/Chimeric approaches


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Muto, D. Tsuchiya, K. Morikawa, and H. Jingami
Structures of the extracellular regions of the group II/III metabotropic glutamate receptors
PNAS, March 6, 2007; 104(10): 3759 - 3764.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Frauli, N. Hubert, S. Schann, N. Triballeau, H.-O. Bertrand, F. Acher, P. Neuville, J.-P. Pin, and L. Prezeau
Amino-Pyrrolidine Tricarboxylic Acids Give New Insight into Group III Metabotropic Glutamate Receptor Activation Mechanism
Mol. Pharmacol., March 1, 2007; 71(3): 704 - 712.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Kuang, Y. Yao, D. MacLean, M. Wang, D. R. Hampson, and B. S. W. Chang
From the Cover: Ancestral reconstruction of the ligand-binding pocket of Family C G protein-coupled receptors
PNAS, September 19, 2006; 103(38): 14050 - 14055.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Wang, Y. Yao, D. Kuang, and D. R. Hampson
Activation of Family C G-protein-coupled Receptors by the Tripeptide Glutathione
J. Biol. Chem., March 31, 2006; 281(13): 8864 - 8870.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
C. Zeitz, M. van Genderen, J. Neidhardt, U. F. O. Luhmann, F. Hoeben, U. Forster, K. Wycisk, G. Matyas, C. B. Hoyng, F. Riemslag, et al.
Mutations in GRM6 Cause Autosomal Recessive Congenital Stationary Night Blindness with a Distinctive Scotopic 15-Hz Flicker Electroretinogram
Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4328 - 4335.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics